Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group.

Abstract

A phase I study of temozolomide administered orally once a day, on 5 consecutive days, between 500 and 1200 mg m(-2) per 28-day cycle was performed. Children were stratified according to prior craniospinal irradiation or nitrosourea therapy. Sixteen of 20 patients who had not received prior craniospinal irradiation or nitrosourea therapy were evaluable… (More)
DOI: 10.1038/bjc.1998.555

Topics

10 Figures and Tables

Cite this paper

@article{Estlin1998PhaseIS, title={Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group.}, author={Edward J Estlin and L. Lashford and Susan Ablett and L. R. Price and Rob Gowing and Ankur A. Gholkar and J. Kohler and Ian J. Lewis and Bruce Morland and Charles Ross Pinkerton and M. C. Stevens and Michelle R Mott and R. Stevens and David R. Newell and D. Walker and C F Dicks-Mireaux and Helene McDowell and Pascale Reidenberg and Paul Statkevich and A. Marco and Vandana Batra and Margaret Dugan and Andrew D. J. Pearson}, journal={British Journal of Cancer}, year={1998}, volume={78}, pages={652 - 661} }